Human Papilloma Virus (HPV) screening PCR kit

Unique detection of 24 high-risk HPV types

HPV stands for Human Papilloma Virus and can cause cervical cancer or genital warts in an infected host. About 80 to 90 percent of the population is sometimes infected with HPV. There are many different HPV types, especially types 16-18 can cause cancer after a long time. HPV type 45 belongs to the HPV18 related alpha-7 species and is responsible for 5 percent of all cervical cancer cases worldwide. In most cases, the host does not notice the infection and the body clears up the virus and thus the infection itself after 1 to 2 years. Types 6 and 11 of HPV are the cause of genital warts. In recent years, an increase has been observed in the number of people who develop cancer after an HPV infection, ie 1,100 women and 400 men in the Netherlands.

The presence of the HPV sample in the test sample can be demonstrated by signals captured in channels FAM (HPV HR), HEX/JOE/VIC (IC), Cy5 (HPV 16), Texas Red/ROX (HPV 18), Cy5.5/Quasar 705 (HPV 45). Diagnosis is made by a host swab from the cervix, vagina and penis. The target sequence to detect HPV from the host are the E1/E2 genes. HPV DNA replication requires the viral E1 and E2 proteins which bind together to the viral origin of replication. This binding forms an E1/E2 ori complex that is essential for initiating DNA replication.

PRODUCT ADVANTAGES

HIGH SPECIFICITY
Unique detection of 24 high-risk HPV types
SELF-SAMPLING OPTION
Validation of self-sampling devices Evalyn Brush (Rovers Medical Devices) and FLOQSwab (COPAN). Supports wide-spreading of HPV screening through simple and comfortable sampling. Housekeeping GAPDH for correct sampling control.
CONTAMINATION PREVENTION
Ready-to-Use Master Mix contains Uracil-DNA glycosylase (UNG) and dUTPs eliminating possible carryover contamination
DIFFERENTIATION OF HIGH-RISK TYPES 16, 18 AND 45
HPV16 and HPV18 are responsible for 70 percent of cervical cancer cases and pre-cancerous cervical lesion. HPV45 is the 3rd most prevalent genotype in cases of invasive cervical cancer worldwide. Enables specific management of patient monitoring and therapy.
COMPLIANCE WITH GUIDELINES FOR HPV SCREENING
German S3-guidelines Prevention of cervical cancer (S3-leitlinie Pravention des Zervixkarzinoms Langverison 1.0 – Dezember 2017). The clinical and reproducibility criteria of the International Guidelines for HPV tests for use in cervical cancer screening

COMPATIBLE WITH A WIDE RANGE OF REAL-TIME PCR DEVICES
CE IVD CERTIFIED DIAGNOSTIC TEST